HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsPricing
Theme 		Help

New: Introducing the Finviz Futures Map

Learn More
Open in Screener

DVAX

Dynavax Technologies Corp

Last Close
Aug 29 • 04:00PM ET
10.12
Dollar change
-0.15
Percentage change
-1.46 		%
Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD
Peers: JNJ PFE MRNA GILD BNTX AZN REGN NVAX VIR VXRT
 | Held by: IJR VTI IWM XBI VXF SPSM IWO IBB IJS PBE
IndexRUT P/E- EPS (ttm)-0.47 Insider Own0.55% Shs Outstand117.23M Perf Week-3.62%
Market Cap1.19B Forward P/E20.87 EPS next Y0.48 Insider Trans-76.66% Shs Float116.62M Perf Month-7.83%
Enterprise Value862.58M PEG- EPS next Q0.13 Inst Own96.80% Short Float11.90% Perf Quarter3.37%
Income-52.73M P/S3.75 EPS this Y-318.39% Inst Trans-13.90% Short Ratio8.28 Perf Half Y-26.61%
Sales316.27M P/B2.40 EPS next Y211.00% ROA-5.45% Short Interest13.87M Perf YTD-20.75%
Book/sh4.22 P/C1.93 EPS next 5Y52.08% ROE-9.28% 52W High14.63 -30.83% Perf Year-9.72%
Cash/sh5.23 P/FCF17.96 EPS past 3/5Y-27.72% - ROIC-7.13% 52W Low9.22 9.76% Perf 3Y-12.83%
Dividend Est.- EV/EBITDA115.78 Sales past 3/5Y-14.08% 51.08% Gross Margin82.83% Volatility2.24% 3.77% Perf 5Y68.39%
Dividend TTM- EV/Sales2.73 EPS Y/Y TTM-419.55% Oper. Margin-0.24% ATR (14)0.37 Perf 10Y-62.90%
Dividend Ex-Date- Quick Ratio6.01 Sales Y/Y TTM26.66% Profit Margin-16.67% RSI (14)39.77 Recom1.80
Dividend Gr. 3/5Y- - Current Ratio6.65 EPS Q/Q65.00% SMA20-4.87% Beta1.24 Target Price23.00
Payout0.00% Debt/Eq0.59 Sales Q/Q29.33% SMA50-4.61% Rel Volume0.70 Prev Close10.27
Employees405 LT Debt/Eq0.50 EarningsAug 07 AMC SMA200-14.11% Avg Volume1.68M Price10.12
IPOFeb 19, 2004 Option/ShortYes / Yes EPS/Sales Surpr.33.33% 10.13% Trades Volume1,164,788 Change-1.46%
Date Action Analyst Rating Change Price Target Change
Feb-11-25Downgrade Goldman Neutral → Sell $15 → $12
Feb-01-24Initiated Goldman Neutral $20
Sep-27-22Initiated JMP Securities Mkt Outperform $22
Jan-06-22Resumed Goldman Buy $38
Aug-06-21Initiated Goldman Buy $19
Aug-07-20Reiterated H.C. Wainwright Buy $14 → $12
Aug-03-20Reiterated H.C. Wainwright Buy $12 → $14
Jun-15-20Initiated Evercore ISI Outperform $14
Oct-18-19Initiated H.C. Wainwright Buy $13
Jul-11-19Upgrade Cantor Fitzgerald Neutral → Overweight $20
Show Previous Ratings
Aug-27-25 04:05PM
Dynavax to Participate in the 2025 Wells Fargo Healthcare Conference
(PR Newswire)
Aug-22-25 07:25AM
Dynavaxs shingles vaccine shows promise in trial against GSKs Shingrix
(Clinical Trials Arena)
Aug-21-25 08:00AM
Dynavax Announces Positive Topline Phase 1/2 Results Supporting Potential Best-in-Class Shingles Vaccine Profile
(PR Newswire) +5.09%
Aug-07-25 05:10PM
Dynavax Technologies (DVAX) Q2 Earnings and Revenues Beat Estimates
(Zacks) -6.60%
04:11PM
Dynavax Technologies: Q2 Earnings Snapshot
(Associated Press Finance)
04:00PM Loading…
04:00PM
Dynavax Reports Second Quarter 2025 Financial Results
(PR Newswire)
Aug-06-25 05:25PM
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates
(Zacks)
Jul-29-25 04:02PM
Dynavax to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025
(PR Newswire)
Jul-28-25 05:20PM
Exelixis (EXEL) Beats Q2 Earnings Estimates
(Zacks)
Jul-06-25 04:15AM
Citizens JMP Reiterates a Buy Rating on Dynavax Technologies (DVAX) With a Price Target of $31
(Insider Monkey)
Jun-11-25 11:01AM
Dynavax Stockholders Elect All Dynavax Director Nominees at 2025 Annual Meeting
(PR Newswire)
Jun-09-25 08:30AM
Deep Track Capital Sends Letter to Dynavax Technologies Shareholders Offering Final Perspectives on Why Change is Needed in the Boardroom
(Business Wire)
07:30AM
Dynavax Urges Stockholders to Support Its Director Nominees at June 11 Annual Meeting
(PR Newswire)
Jun-04-25 04:59PM
Dynavax Comments on Glass Lewis Recommendation
(PR Newswire)
09:27AM
Glass Lewis Recommends Shareholders Support Deep Track's Case for Board Change at Dynavax Technologies
(Business Wire)
04:10PM Loading…
May-28-25 04:10PM
Dynavax to Present at William Blair's 45th Annual Growth Stock Conference
(PR Newswire)
May-23-25 06:12PM
Deep Track Capital Comments on ISS Recommendation
(Business Wire)
01:44PM
Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote "FOR" All Four of Dynavax's Highly Qualified Director Nominees
(PR Newswire)
May-15-25 04:00PM
Deep Track Capital Issues Letter to Fellow Dynavax Technologies Shareholders Detailing Critical Issues in Advance of Annual Meeting
(Business Wire)
May-12-25 07:30AM
Dynavax Files Investor Presentation Highlighting Superior Strategy and Board That is Delivering Strong Financial Results and Significant Long-Term Value
(PR Newswire)
May-09-25 08:38PM
/C O R R E C T I O N -- Dynavax Technologies/
(PR Newswire)
May-08-25 12:00PM
Dynavax Technologies (DVAX) Upgraded to Buy: Here's Why
(Zacks)
May-07-25 04:45PM
Dynavax Issues Statement and Mails Letter to Stockholders Emphasizing Record Financial Results and Continued Momentum
(PR Newswire) -10.99%
03:19AM
Dynavax Technologies Corp (DVAX) Q1 2025 Earnings Call Highlights: Record Revenue and Strategic ...
(GuruFocus.com)
May-06-25 05:15PM
Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates
(Zacks)
04:01PM
Dynavax Reports First Quarter 2025 Financial Results and Announces New Pipeline Programs
(PR Newswire)
08:00AM
Deep Track Capital Releases Investor Presentation on Dynavax Technologies
(Business Wire)
May-05-25 08:10AM
TG Therapeutics (TGTX) Lags Q1 Earnings Estimates
(Zacks)
May-01-25 08:00AM
Dynavax Announces Nationwide Harris Poll Survey Results Finding Americans Underestimate the Serious Consequences of Hepatitis B and Vaccine Protection Benefits
(PR Newswire)
Apr-29-25 07:30AM
Dynavax Highlights Superior Board Leadership Overseeing Long-Term Value Creation Strategy
(PR Newswire)
04:00PM Loading…
Apr-22-25 04:00PM
Dynavax to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025
(PR Newswire)
Apr-21-25 04:05PM
Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders
(Business Wire)
Apr-17-25 09:17AM
GSK's Pentavalent Meningococcal Jab Recommended for Use by ACIP
(Zacks)
07:15AM
Dynavax Files Definitive Proxy Statement and Sends Letter to Stockholders
(PR Newswire)
Apr-16-25 09:48AM
MURA Soars as it Explores Strategic Options Post Cancer Study Failures
(Zacks) -6.66%
08:52AM
DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up
(Zacks)
08:00AM
Deep Track Capital Comments on Dynavax Technologies Rejection of Most Recent Settlement Offer
(Business Wire)
Apr-15-25 10:20AM
Buy The Dips, Sell The Rips
(Seeking Alpha)
Apr-11-25 11:57AM
KROS Initiates Exploring Strategic Alternatives, Stock Gains 18.5%
(Zacks)
Apr-10-25 10:53AM
PHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next Dose
(Zacks) -8.81%
09:58AM
ANIX Gets New Patent for Breast Cancer Vaccine Technology, Stock Up
(Zacks)
Apr-09-25 12:57PM
3 Biotech Stocks Holding Their Own
(Seeking Alpha)
10:01AM
RXRX Doses First Patient in Early-Stage B-Cell Lymphomas Study
(Zacks)
Apr-08-25 12:18PM
AtriCure Drops 25%: Bargain Or Caution Sign?
(Seeking Alpha) -5.92%
11:29AM
PCRX Stock Soars on Exparel Patent Settlement With Generic Players
(Zacks)
11:21AM
RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study
(Zacks)
Apr-07-25 10:53AM
AZN Gets EU Nod for Expanded Use of Two Separate Cancer Drugs
(Zacks)
Apr-04-25 01:45PM
Bayer's Vividion Initiates Dosing in Early-Stage Cancer Study
(Zacks)
01:10PM
AMGN's Uplizna Gets FDA Nod for 2nd Rare Autoimmune Disease Indication
(Zacks)
09:37AM
PCRX Doses First Patient in Phase II PCRX-201 Gene Therapy Study
(Zacks)
Apr-03-25 05:40PM
Dynavax Files Preliminary Proxy Statement
(PR Newswire)
11:27AM
SNY's Rilzabrutinib Gets FDA's Orphan Drug Tag for Two Rare Diseases
(Zacks)
09:32AM
DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up
(Zacks)
Apr-02-25 11:29AM
AXSM Stock Down on Top-Line Data From Depression Study on Solriamfetol
(Zacks)
Apr-01-25 10:55AM
VRTX Provides Mixed Updates for Type 1 Diabetes Pipeline Candidates
(Zacks)
09:31AM
AstraZeneca's Imfinzi Gets FDA Nod for Bladder Cancer Indication
(Zacks)
Mar-31-25 09:57AM
Moderna, biotech stocks slide following resignation of FDA official Peter Marks
(Yahoo Finance) -5.19%
Mar-28-25 09:45AM
Kodiak Q4 Loss Narrower Than Expected, Pipeline Development in Focus
(Zacks)
09:26AM
BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance
(Zacks)
Mar-27-25 12:37PM
Bayer Licenses PRMT5 inhibitor From Suzhou Puhe BioPharma
(Zacks)
09:39AM
PLRX Stock Plunges 89% in 3 Months: Here's What Investors Should Know
(Zacks)
Mar-25-25 12:44PM
Will Alkermes' Proprietary Drugs Aid Growth Amid Stiff Competition?
(Zacks)
11:51AM
UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study
(Zacks)
Mar-24-25 02:36PM
EMA Accepts GSK's Filing for Expanded Use of Nucala in COPD
(Zacks)
Mar-21-25 12:46PM
Alnylam Gets FDA Nod for Expanded Use of Amvuttra in Cardiomyopathy
(Zacks)
12:44PM
OPTN Stock Soars 53% on Inking $330M Deal to be Acquired by Paratek
(Zacks)
12:39PM
Pacira Surges 66.8% in Six Months: How Should You Play the Stock?
(Zacks)
12:37PM
Mirum's Heavy Dependence on Livmarli for Revenues Remains a Woe
(Zacks)
12:17PM
PSTV Stock Surges as FDA Accepts Proprietary Name for Lead Drug
(Zacks)
09:26AM
ESPR to Study Bempedoic Acid in Pediatric Familial Hypercholesterolemia
(Zacks)
Mar-20-25 12:23PM
Puma Biotechnology Stock Rises 35% in 6 Months: Here's Why
(Zacks)
10:44AM
Why Dynavax Technologies (DVAX) Stock Might be a Great Pick
(Zacks)
10:19AM
IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success
(Zacks)
09:34AM
Novartis Reports Updated Positive Data From Phase III SMA Program
(Zacks)
Mar-19-25 10:59AM
JNJ's Nipocalimab Gets FDA's Fast Track Tag for Sjogren's Disease
(Zacks)
Mar-12-25 09:55AM
Wall Street Analysts See an 83.1% Upside in Dynavax Technologies (DVAX): Can the Stock Really Move This High?
(Zacks)
Mar-10-25 08:00AM
Deep Track Capital Sends Letter to Dynavax Technologies Board of Directors
(Business Wire)
Mar-06-25 06:00AM
Dynavax Announces Convertible Debt Refinancing and Common Stock Share Repurchase
(PR Newswire)
Mar-02-25 12:36PM
Is Dynavax Technologies Corporation (DVAX) the Best Small Cap Pharma Stock to Buy Now?
(Insider Monkey)
Feb-25-25 04:10PM
Dynavax to Participate in Upcoming Investor Conferences
(PR Newswire)
Feb-24-25 09:55AM
Wall Street Analysts Think Dynavax Technologies (DVAX) Could Surge 81.92%: Read This Before Placing a Bet
(Zacks)
Feb-21-25 12:59PM
MercadoLibre Stock Hits New High As Company Delivers Profits
(Investor's Business Daily)
02:14AM
Dynavax Technologies Corp (DVAX) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ...
(GuruFocus.com)
Feb-20-25 09:30PM
Dynavax Technologies (DVAX) Q4 2024 Earnings Call Transcript
(Motley Fool)
05:10PM
Dynavax Technologies (DVAX) Surpasses Q4 Earnings and Revenue Estimates
(Zacks)
04:15PM
Dynavax Technologies: Q4 Earnings Snapshot
(Associated Press Finance)
04:01PM
Dynavax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Financial Guidance
(PR Newswire)
Feb-19-25 04:52PM
Dynavax Responds to Deep Track and Highlights Long-Term Value Creation Strategy
(PR Newswire)
09:00AM
Deep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies Board of Directors at 2025 Annual Meeting
(Business Wire)
08:04AM
Investor Deep Track launches proxy fight at Dynavax, nominates 4 directors
(Reuters)
Feb-11-25 03:11PM
Goldman Sachs Turns Bearish On Vaccine Maker Dynavax Amid Shingles And Hepatitis B Uncertainty
(Benzinga)
Feb-06-25 05:42PM
Dynavax to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on February 20, 2025
(PR Newswire)
Jan-29-25 09:55AM
Wall Street Analysts Believe Dynavax Technologies (DVAX) Could Rally 93.2%: Here's is How to Trade
(Zacks)
Jan-27-25 06:00AM
Dynavax Advances Board Refreshment Program
(PR Newswire)
Jan-16-25 12:00PM
Dynavax Technologies (DVAX) Upgraded to Buy: Here's What You Should Know
(Zacks)
Jan-14-25 09:29AM
Dynavax Reports Revenue Growth and Defense Contract
(TipRanks)
Jan-13-25 09:00AM
Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Highlights
(PR Newswire)
Jan-03-25 08:30AM
Implied Volatility Surging for Dynavax Technologies (DVAX) Stock Options
(Zacks)
Nov-27-24 09:55AM
Does Dynavax Technologies (DVAX) Have the Potential to Rally 93.52% as Wall Street Analysts Expect?
(Zacks)
Nov-26-24 04:05PM
Dynavax to Present at the 7th Annual Evercore HealthCONx Conference
(PR Newswire)
Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Myers Scott DunsethDirectorAug 22 '25Buy10.823,80041,11635,004Aug 25 08:50 AM
Deep Track Biotechnology Maste10% OwnerAug 21 '25Sale11.031,094,99412,077,78416,696,492Aug 22 08:49 PM
Deep Track Biotechnology Maste10% OwnerAug 22 '25Sale10.59970,14310,273,81415,726,349Aug 22 08:49 PM
Novack David FPresident & COOMar 24 '25Option Exercise6.8010,00068,05018,078Mar 26 05:04 PM
Novack David FPresident & COOMar 24 '25Sale14.0010,000140,0008,078Mar 26 05:04 PM
DAVID NOVACKOfficerMar 24 '25Proposed Sale14.0010,000140,000Mar 24 04:23 PM
Novack David FPresident & COOMar 18 '25Sale13.5814,020190,3928,078Mar 20 06:15 PM
DAVID NOVACKOfficerMar 18 '25Proposed Sale13.5814,020190,386Mar 18 04:17 PM
Novack David FPresident & COOMar 07 '25Sale14.3932,764471,47422,098Mar 10 09:44 PM
DAVID NOVACKOfficerMar 07 '25Proposed Sale14.3932,764471,376Mar 07 05:16 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Open in Screener

ZNTL

Zentalis Pharmaceuticals Inc

Last Close
Aug 29 • 04:00PM ET
1.69
Dollar change
-0.07
Percentage change
-3.98 		%
Healthcare • Biotechnology • USA • NASD
ZNTL Zentalis Pharmaceuticals Inc daily Stock Chart
Peers: BMY LLY PFE JNJ MRK AMGN GILD BIIB VRTX REGN
 | Held by: VTI VXF SCHA PRFZ FESM IWC VHT DFAS FSCC BTEC
Index- P/E- EPS (ttm)-2.28 Insider Own20.68% Shs Outstand72.14M Perf Week-15.08%
Market Cap121.91M Forward P/E- EPS next Y-2.07 Insider Trans0.14% Shs Float57.22M Perf Month22.46%
Enterprise Value-140.20M PEG- EPS next Q-0.53 Inst Own73.40% Short Float7.80% Perf Quarter39.67%
Income-162.78M P/S4.54 EPS this Y7.24% Inst Trans-6.22% Short Ratio4.51 Perf Half Y-18.36%
Sales26.86M P/B0.44 EPS next Y4.44% ROA-38.60% Short Interest4.46M Perf YTD-44.22%
Book/sh3.81 P/C0.40 EPS next 5Y8.39% ROE-49.55% 52W High5.44 -68.93% Perf Year-44.59%
Cash/sh4.21 P/FCF- EPS past 3/5Y14.39% -12.89% ROIC-52.14% 52W Low1.01 67.33% Perf 3Y-93.98%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin96.05% Volatility8.26% 7.92% Perf 5Y-94.95%
Dividend TTM- EV/Sales-5.22 EPS Y/Y TTM17.10% Oper. Margin-633.83% ATR (14)0.13 Perf 10Y-
Dividend Ex-Date- Quick Ratio7.99 Sales Y/Y TTM-33.76% Profit Margin-605.93% RSI (14)55.13 Recom2.11
Dividend Gr. 3/5Y- - Current Ratio7.99 EPS Q/Q69.96% SMA205.26% Beta1.78 Target Price6.19
Payout- Debt/Eq0.15 Sales Q/Q- SMA5016.99% Rel Volume0.57 Prev Close1.76
Employees166 LT Debt/Eq0.14 EarningsAug 06 AMC SMA200-13.67% Avg Volume989.13K Price1.69
IPOApr 03, 2020 Option/ShortYes / Yes EPS/Sales Surpr.37.67% - Trades Volume560,361 Change-3.98%
Date Action Analyst Rating Change Price Target Change
Aug-12-24Upgrade Wedbush Underperform → Neutral $4
Jun-20-24Downgrade UBS Buy → Neutral $28 → $5
Jun-18-24Downgrade Wells Fargo Overweight → Equal Weight
Jun-18-24Downgrade Wedbush Neutral → Underperform $15 → $4
Jun-18-24Downgrade Morgan Stanley Overweight → Equal-Weight $38 → $8
Jun-18-24Downgrade Jefferies Buy → Hold $42 → $6
Nov-08-23Downgrade Wedbush Outperform → Neutral $38 → $12
Nov-07-23Downgrade Leerink Partners Outperform → Market Perform $15
Jul-12-22Initiated Cowen Outperform
Apr-06-22Initiated Wells Fargo Overweight $67
Show Previous Ratings
Aug-28-25 04:15PM
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
(GlobeNewswire)
Aug-26-25 04:05PM
Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary
(GlobeNewswire)
Aug-06-25 04:05PM
Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress
(GlobeNewswire) +5.07%
Jul-01-25 05:00PM
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Jun-02-25 05:00PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) +5.79% +6.25%
04:05PM Loading…
May-14-25 04:05PM
Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress
(GlobeNewswire) +5.88%
May-01-25 05:00PM
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Apr-28-25 08:00AM
Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC
(GlobeNewswire)
Apr-23-25 04:05PM
Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting
(GlobeNewswire)
Apr-01-25 05:30PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) -12.58%
Mar-26-25 04:05PM
Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates
(GlobeNewswire) -5.88%
Mar-25-25 04:40PM
Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025
(GlobeNewswire) -5.56%
Mar-15-25 11:25AM
Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer
(GlobeNewswire)
Mar-03-25 05:00PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) -7.25%
08:00AM
Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer
(GlobeNewswire)
04:05PM Loading…
Feb-24-25 04:05PM
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
(GlobeNewswire)
Feb-21-25 12:21AM
Zentalis Pharmaceuticals (ZNTL): Among Cheapest Stocks Insiders Are Buying Recently
(Insider Monkey) -6.07%
Feb-03-25 05:42PM
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
09:35AM
Zentalis Pharmaceuticals (ZNTL) Loses -46.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
(Zacks)
Jan-30-25 10:20AM
Zentalis price target lowered to $10 from $20 at Oppenheimer
(TipRanks) -12.17%
Jan-29-25 07:00AM
Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer
(GlobeNewswire) -21.25%
Jan-28-25 04:05PM
Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development
(GlobeNewswire)
Jan-09-25 12:00PM
Zentalis Pharmaceuticals (ZNTL) Upgraded to Strong Buy: What Does It Mean for the Stock?
(Zacks)
07:00AM
Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies
(GlobeNewswire)
Jan-02-25 04:53PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) +8.00%
Dec-12-24 07:00AM
Zentalis Pharmaceuticals Announces Key Management Appointments
(GlobeNewswire) -10.57%
Dec-02-24 04:35PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) -8.20%
Nov-13-24 08:00AM
Zentalis Pharmaceuticals Announces Executive Leadership Changes Supporting Planned Registrational Clinical Studies of Azenosertib
(GlobeNewswire) +5.66%
Nov-01-24 07:04PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) +21.61% +12.35%
Oct-18-24 03:05PM
State Street Corp's Strategic Reduction in Zentalis Pharmaceuticals Holdings
(GuruFocus.com)
03:03PM Loading…
Oct-07-24 03:03PM
FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc
(GuruFocus.com) -7.72%
Sep-17-24 12:15PM
FDA lifts partial clinical hold on Zentalis Pharmas cancer WEE1 inhibitor
(Pharmaceutical Technology) +11.41%
Sep-16-24 09:00AM
FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers
(Benzinga) +13.58%
07:00AM
Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies
(GlobeNewswire)
Sep-09-24 07:00AM
Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024
(GlobeNewswire)
Sep-03-24 04:40PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) -6.92%
Aug-26-24 11:58AM
Zentalis (ZNTL) Plunges More Than 70% in 3 Months: Here's Why
(Zacks)
Aug-09-24 02:53PM
ZNTL Stock Earnings: Zentalis Pharma Misses EPS for Q2 2024
(InvestorPlace) -9.37%
07:00AM
Zentalis Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Progress
(GlobeNewswire)
Aug-01-24 06:00PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) -5.00%
Jul-01-24 06:00PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) -14.80%
Jun-19-24 10:23AM
Zentalis (ZNTL) Tanks After FDA Puts 3 Cancer Studies on Hold
(Zacks)
04:52AM
FDA places partial clinical hold on Zentalis trials of azenosertib for cancer
(Clinical Trials Arena)
Jun-18-24 07:00AM
Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program
(GlobeNewswire) -50.66%
Jun-03-24 06:00PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Jun-01-24 02:43AM
Insider Selling at Zentalis Pharmaceuticals Inc (ZNTL): President, Interim CFO Cam Gallagher ...
(GuruFocus.com)
May-30-24 07:00AM
Zentalis Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
(GlobeNewswire)
May-29-24 07:00AM
Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of Directors
(GlobeNewswire)
May-23-24 05:01PM
Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting
(GlobeNewswire) -5.84%
May-14-24 07:00AM
Zentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation Summit
(GlobeNewswire)
May-08-24 10:27AM
Stifel Adjusts Price Target on Zentalis Pharmaceuticals to $32 From $36, Maintains Buy Rating
(MT Newswires)
May-07-24 09:04PM
Zentalis Pharmaceuticals Reports Q1 2024 Earnings: Surpasses Revenue Forecasts with Strategic ...
(GuruFocus.com) +5.03%
01:54PM
ZNTL Stock Earnings: Zentalis Pharma Beats EPS, Beats Revenue for Q1 2024
(InvestorPlace)
07:00AM
Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress
(GlobeNewswire)
May-01-24 05:30PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Apr-02-24 04:05PM
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024
(GlobeNewswire) -10.54% +8.25%
Apr-01-24 05:30PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Mar-01-24 06:00PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Feb-28-24 09:55AM
Wall Street Analysts Think Zentalis Pharmaceuticals, Inc. (ZNTL) Could Surge 136.44%: Read This Before Placing a Bet
(Zacks) +5.30%
07:00AM
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
(GlobeNewswire)
Feb-27-24 07:01PM
Zentalis Pharmaceuticals Inc (ZNTL) Reports Full Year 2023 Financial Results and Provides ...
(GuruFocus.com)
07:00AM
Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates
(GlobeNewswire)
Feb-14-24 09:35AM
Down -19.06% in 4 Weeks, Here's Why You Should You Buy the Dip in Zentalis Pharmaceuticals, Inc. (ZNTL)
(Zacks) +10.34%
Feb-13-24 07:00AM
Zentalis Pharmaceuticals to Participate in the Oppenheimer Healthcare Life Sciences Conference
(GlobeNewswire) -5.83%
Feb-08-24 12:00PM
What Makes Zentalis Pharmaceuticals, Inc. (ZNTL) a New Buy Stock
(Zacks)
Feb-05-24 11:26PM
Insider Sell: President Cam Gallagher Sells 11,552 Shares of Zentalis Pharmaceuticals Inc (ZNTL)
(GuruFocus.com)
Feb-01-24 05:00PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Jan-25-24 07:00AM
Zentalis Pharmaceuticals Strengthens Management Team with Key Appointments
(GlobeNewswire)
Jan-08-24 07:00AM
Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform
(Business Wire) +7.15%
Jan-02-24 04:49PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) +5.54%
Dec-01-23 05:39PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Nov-13-23 09:03PM
Director David Johnson's Strategic Purchase of Zentalis Pharmaceuticals Inc Shares
(GuruFocus.com) +14.42%
Nov-09-23 07:00AM
Zentalis to Participate in Investor Call Focused on Ovarian Cancer with Gynecologic Oncology Key Opinion Leader Joyce F. Liu, M.D., MPH, Hosted by TD Cowen
(GlobeNewswire)
Nov-06-23 07:13PM
Zentalis Pharmaceuticals Inc (ZNTL) Reports Q3 2023 Financial Results and Operational Updates
(GuruFocus.com) -30.20% -18.27%
07:18AM
Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
(GlobeNewswire)
Nov-01-23 04:52PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Oct-07-23 05:00AM
Insider Sell: Chief Medical Officer Carrie Brownstein Sells 10,628 Shares of Zentalis ...
(GuruFocus.com)
Oct-02-23 04:27PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Sep-14-23 01:02AM
Director Jan Skvarka Sells 5,000 Shares of Zentalis Pharmaceuticals Inc (ZNTL)
(GuruFocus.com)
Sep-06-23 07:00AM
Zentalis Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
(GlobeNewswire)
Sep-01-23 04:37PM
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) -6.34%
Aug-09-23 07:00AM
Zentalis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates
(GlobeNewswire)
Aug-01-23 04:28PM
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
07:00AM
Zentalis Pharmaceuticals Appoints Kimberly Freeman as Chief Strategy Officer
(GlobeNewswire)
Jun-15-23 06:01AM
Zentalis Pharmaceuticals Announces Pricing of Underwritten Offering of Common Stock
(GlobeNewswire) +12.67%
Jun-06-23 06:00AM
Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing
(GlobeNewswire)
Jun-02-23 02:34PM
Why Shares of Zentalis Pharmaceuticals Dropped This Week
(Motley Fool)
May-26-23 12:33PM
Wells Fargo Predicts up to 70% Rally for These 2 Stocks Heres Why They Have Solid Upside
(TipRanks) +10.64%
10:53AM
Zentalis Gears Up for Phase 3 Study of Azenosertib after Positive Phase 1b Outcomes
(Benzinga)
May-25-23 05:38PM
Zentalis Announces Presentation of Positive Phase 1b Data Demonstrating Durable Responses and Favorable Safety Profile of Azenosertib in Combination with Chemotherapy at the 2023 ASCO Annual Meeting
(GlobeNewswire)
May-23-23 07:00AM
Zentalis to Host Investor Call to Provide Clinical Update with Safety, Pharmacology, and Efficacy Results for Azenosertib Monotherapy and Development Plans for Monotherapy and Chemotherapy Combinations
(GlobeNewswire)
May-12-23 09:55AM
Wall Street Analysts Believe Zentalis Pharmaceuticals, Inc. (ZNTL) Could Rally 95.67%: Here's is How to Trade
(Zacks)
May-10-23 07:00AM
Zentalis Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates
(GlobeNewswire) +6.93%
Apr-26-23 10:00AM
Zentalis to present positive clinical data in ovarian cancer combining azenosertib and chemotherapy, including clinical support for Cyclin E1 expression as predictive marker for clinical benefit from azenosertib at the 2023 ASCO Annual Meeting
(GlobeNewswire)
Apr-17-23 09:00AM
Zentalis Announces Preclinical Data Supporting Cyclin E1 As A Predictive Marker For Azenosertib Treatment At AACR Annual Meeting 2023
(GlobeNewswire) +7.51%
Mar-01-23 07:00AM
Zentalis Pharmaceuticals Reports Full Year 2022 Financial Results and Operational Updates
(GlobeNewswire)
Feb-13-23 07:00AM
Zentalis Pharmaceuticals Appoints Dr. Iris Roth as Chief Operating Officer
(GlobeNewswire)
Feb-01-23 05:00PM
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
07:01AM
Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences
(GlobeNewswire)
Jan-17-23 09:18AM
We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely
(Simply Wall St.)
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Myers Scott DunsethDirectorApr 30 '25Buy1.4021,00029,373281,192Apr 30 05:07 PM
Bruns IngmarChief Medical OfficerFeb 06 '25Buy2.2820,00045,65636,629Feb 12 05:00 PM
Cam GallagherFormer DirectorFeb 11 '25Proposed Sale2.006871,374Feb 11 08:06 PM
Vultaggio VincentPAO and Interim PFOFeb 03 '25Sale1.712,6154,476189,826Feb 05 06:33 PM
Lackner MarkChief Scientific OfficerFeb 03 '25Sale1.7114,36824,591512,856Feb 05 06:32 PM
Paul AndreaChief Legal OfficerFeb 03 '25Sale1.7113,23022,6431,070,784Feb 05 06:31 PM
Skvarka JanDirectorJan 31 '25Buy1.7260,000103,446149,551Feb 04 04:45 PM
Walker Luke NathanielDirectorJan 31 '25Buy1.7614,20024,96686,681Feb 04 04:43 PM
EASTLAND JULIA MARIECEO & PresidentJan 31 '25Buy1.7328,50049,34528,500Feb 04 04:37 PM
Mark LacknerChief Scientific OfficerFeb 03 '25Proposed Sale1.7114,36824,591Feb 03 07:14 PM
Andrea PaulChief Legal Officer & CorporatFeb 03 '25Proposed Sale1.7113,23022,643Feb 03 07:13 PM
Cam GallagherFormer DirectorFeb 03 '25Proposed Sale1.7128,55848,877Feb 03 07:12 PM
Lackner MarkChief Scientific OfficerJan 02 '25Sale3.124,41113,762191,317Jan 03 05:17 PM
Diana HausmanFormer Chief Medical OfficerOct 31 '24Proposed Sale2.869,88828,294Oct 31 08:59 PM
Vultaggio VincentPrincipal Accounting OfficerOct 04 '24Sale3.181,6035,09833,855Oct 04 06:01 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.